Human fibroblasts weakly activated the alternative complement pathway, as assessed by C3b deposition, while 4-to 5-fold more C3b was observed 4 days after infection on cytomegalovirus (CMV)-infected fibroblasts when incubated with human serum. CMV-infected fibroblasts activated via the classical complement pathway independent of specific anti-CMV antibody and incubation of CMV-infected fibroblasts with serum deficient in complement components revealed that C1q, but not mannan-binding lectin, was required for complement activation. The enhanced complement activation by CMV-infected cells was observed as early as 4 h after infection and required the active transcription of CMV genes. No difference in the complement activation by CMV-infected cells was observed with the use of CMVseropositive or -seronegative serum as a complement source, suggesting that CMV infection induces or up-regulates a protein that binds directly to C1q in a complement-activating conformation.
Human fibroblasts weakly activated the alternative complement pathway, as assessed by C3b deposition, while 4-to 5-fold more C3b was observed 4 days after infection on cytomegalovirus (CMV)-infected fibroblasts when incubated with human serum. CMV-infected fibroblasts activated via the classical complement pathway independent of specific anti-CMV antibody and incubation of CMV-infected fibroblasts with serum deficient in complement components revealed that C1q, but not mannan-binding lectin, was required for complement activation. The enhanced complement activation by CMV-infected cells was observed as early as 4 h after infection and required the active transcription of CMV genes. No difference in the complement activation by CMV-infected cells was observed with the use of CMVseropositive or -seronegative serum as a complement source, suggesting that CMV infection induces or up-regulates a protein that binds directly to C1q in a complement-activating conformation.
Complement forms the first line of defense against invading pathogens. Activation of the alternative pathway efficiently removes many types of bacteria long before the antibody or cellular immune response arises. After the host produces antibodies, the classical activation pathway of complement can assist the inactivation of many pathogens, including herpes simplex virus (HSV) [1, 2] and cytomegalovirus (CMV) [3] [4] [5] . However, CMV-infected fibroblasts are resistant to complement-mediated lysis, even in the presence of specific anti-CMV antibodies in the serum [6, 7] . Only serum samples from patients acutely infected with CMV lyse CMV-infected cells and then only late in the viral replication cycle, long after the production of infectious virus occurred. Recently, we found a partial explanation for this complement resistance by showing that CMV infection of fibroblasts results in the increased expression of several host-encoded complement regulators-decayaccelerating factor (CD55) and membrane cofactor protein (CD46)-but not the terminal pathway regulator, CD59 [8] . We found that while no lysis of uninfected or CMV-infected fibroblasts occurred unless the intrinsic CD59 was blocked, once CD59 was blocked, the CMV-infected cells were always less susceptible to complement-mediated lysis than were the mockinfected controls, and this protection became more pronounced with increasing length of infection. In the present study, we A, Uniform infection of all fibroblasts shown by cell-surface expression of major CMV envelope glycoprotein, gB, detected by monoclonal antibody (MAb). CMV protein expression levels 24 and 72 h after infection (pi) are compared with results from mock-infected fibroblasts (0 h pi), which gave same profile as isotype-matched control antibody incubated with CMV-infected fibroblasts (control). B, Increasing C3 deposition detected by MAb reactive with C3b/iC3b at 24 and 72 h pi vs. C3 deposition on mock-infected fibroblasts (0 h pi). Nonspecific binding of anti-C3b/iC3b MAb was same for mock-and CMV-infected cells not incubated with serum (no serum). C, C3b/iC3b deposition on mock-infected (stars) or CMV-infected fibroblasts at different times after infection detected by flow cytometry with MAbs. 2 different serum samples containing specific anti-CMV antibodies (Ⅵ, ࡗ) were compared with seronegative (ⅷ) sample. Each point is mean of duplicate determinations.
IgG-seropositive were devoid of anti-IgM antibodies, but IgMseropositive samples frequently contained anti-CMV IgG.
Antibodies Murine monoclonal antibodies (MAbs) directed against C3c were purchased from Quidel (San Diego); MAb C3/ 30, which reacts with C3b and iC3b but not with native C3 [9] , was a gift of P. Taylor (CIBA-GEIGY, Horsham, UK). Peroxidaseconjugated goat anti-rabbit IgG or fluorochrome-conjugated goat anti-mouse IgG antisera were purchased from Jackson Immunoresearch (Avondale, PA). Fluorescein isothiocyanate (FITC)-labeled rabbit polyclonal anti-goat IgG, mouse anti-human IgG Fc, rabbit anti-sheep IgG, and goat anti-rabbit IgG were purchased from Sigma. The following polyclonal antisera were also purchased from Sigma: sheep anti-C4, sheep anti-C2, rabbit anti-C4, and goat anti-C1q. Rabbit polyclonal antiserum specific for human C3 was raised in our laboratory. Monoclonal anti-CMV gB was a gift of L. K. Borysiewicz (University of Wales College of Medicine).
Virus infection. Human CMV laboratory strain AD169 was used to infect cells at an MOI of 10, unless otherwise stated. UV light was used to inactivate CMV by exposing virus stocks to a short wavelength UV (312 nm) light source for 20 min. Conditions for inactivation were determined empirically; stocks were considered UV-inactivated when the CMV stock failed to induce cytopathic effects when incubated with fibroblasts for extended periods of time.
Complement attack.
Fibroblasts were seeded into 24-well plates ( cells/well), allowed to grow overnight, infected the 5 5 ϫ 10 next morning, and allowed to continue in culture until use at various time points after infection. Adherent cells were washed twice with PBS before addition of 0.25 mL per well of serum diluted 1: 5 with veronal-buffered saline (VBS). Total blocking of complement activation was achieved by chelation of Ca 2ϩ and Mg 2ϩ by addition of EDTA to the serum sample to a final concentration of 15 mM; 15 mM EGTA/30 mM MgCl 2 was used to chelate Ca 2ϩ and to specifically block the classical activation pathway. Serum was incubated with the cells for 5-30 min at 37ЊC in a 5% CO 2 incubator as indicated in the Results section. The cells were then washed twice with PBS and overlaid with PBS containing 15 mM EDTA, 30 mM sodium azide, and 1% bovine serum albumin. Cells were disaggregated with a 1-mL pipette and prepared for flow cytometry. Nonspecific binding of C3 or of the MAbs used to detect C3 was investigated by incubating the mock-or CMV-infected cells with serum diluted in VBS in the presence of 15 mM EDTA.
Flow cytometry studies. Conditions for flow cytometry are given elsewhere [8] . For all flow cytometry experiments, each triplicate sample was split into two equal halves; one half was incubated with the specific antiserum and the other half with an isotypematched control. Matched background values were subtracted from the specific values prior to statistical analysis. Phycoerythrinlabeled secondary antibodies were used to detect all mouse and rabbit primary antibodies, while FITC-labeled secondary antibodies were used to detect primary antibodies from all remaining species. Flow cytometry was performed on a flow cytometer (FACScalibur; Becton-Dickinson, Oxford, UK). Statistical analysis consisted of one-way analysis of variance and post-hoc analysis using Fisher's least significance test; Bonferroni's correction for multiple comparisons was used to identify differences between groups.
Radiolabeled C1q studies. C1q was radiolabeled with ]-C1q was harvested by rinsing the well with 2% SDS and 0.1% Triton X-100 in distilled water. Radioactivity was counted by gamma counter. All points were in triplicate, and the study was done twice.
Results

Complement activation by uninfected fibroblasts.
Primary explant neonatal foreskin fibroblasts were incubated with a 1:5 dilution of normal human serum for 30 min at 37ЊC; low levels of C3b or iC3b were deposited on the surface as detected by flow cytometry utilizing 2 MAbs (figure 1C). Little variation in C3b deposition was detected between serum samples from several persons; however, some variation (range, 20-100 fluorescent U) was observed among 6 different sources of fibroblasts (data not shown). Furthermore, more C3b was deposited on fibroblasts that had been in culture 115 serial passages (data not shown). Therefore, the same source of fibroblasts was used for all matched experiments, and all experiments were conducted on cells at !15 serial passages.
Increased complement activation by CMV-infected fibroblasts. We consistently found more C3b deposition on CMVinfected fibroblasts than on mock-infected controls. The fibroblasts were uniformly infected with CMV as shown by the uniform increase in cell-surface expression of CMV gB over time ( figure 1A ). Following incubation with normal human serum, the level of C3 deposited on the CMV-infected cells also increased on the entire population of cells (figure 1B). Using 6 different serum samples, determined by ELISA to be devoid of anti-CMV antibodies, the C3b deposition on CMV-infected fibroblasts increased by an average of 4.6-fold compared with mock-infected cells 3-4 days after infection (mean of 10 separate experiments done in triplicate; range, 1.9-to 13.6-fold). On CMV-infected cells, C3b deposition increased rapidly from the start of infection to 16 h after infection and continued to increase slowly to the end of the experiment (72 h after infection; figure 1C) .
No difference in C3b deposition was seen between sera containing anti-CMV antibodies and those devoid of anti-CMV antibodies. This finding was confirmed by incubating 5 additional sera (3 seronegative and 2 seropositive samples) with mock-infected and CMV-infected fibroblasts 40 h after infection ( figure 2A) . Binding of CMV-specific IgG to the surface of CMV-infected cells incubated with CMV-seropositive serum was clearly demonstrable by flow cytometry (figure 2B). None of these IgG-seropositive serum samples contained specific anti-CMV IgM. These experiments were repeated using human sera (diluted 1:10 in VBS) categorized as follows: CMV-seronegative ( ), CMV IgG-seropositive ( ), or CMV IgM-seron ϭ 4 n ϭ 3 positive ( ). No difference in C3b deposition on infected n ϭ 4 cells was observed between any of these serum types (data not shown). The increase in complement activation on CMV-infected fibroblasts was seen as early as 4 h after infection (  ; table 1 ) and required transcription of CMV genes, as P ϭ .01 no increase over uninfected controls was seen for cells incubated in parallel with short-wave UV-inactivated CMV 4 h after infection (table 1) or later (data not shown).
The binding of anti-C3/iC3b MAb to CMV-infected or uninfected cells incubated with serum with EDTA was the same Antibody-independent classical pathway activation by CMVinfected cells. The low level of complement activation by uninfected fibroblasts was little affected by the inhibition of the classical pathway; C3b deposition was reduced by 0%-30% in all experiments (figure 3). In contrast, incubation of CMVinfected fibroblasts with serum in the presence of EGTA-MgCl 2 to inhibit the classical pathway reduced C3b deposition to the level observed on uninfected fibroblasts (figure 3). EDTA inhibits the activation of both the alternative and classical pathways, and no binding of C3 fragments to uninfected or CMVinfected cells was seen in the presence of EDTA, indicating that the C3 fragment deposition on the cells requires complement activation and does not occur in a passive or nonspecific fashion (figure 3). Incubation with heat-treated serum (56ЊC, 30 min) gave similar results, confirming the requirement for a functional complement system. The data indicate that CMV infection of fibroblasts induced activation of the classical pathway. In support of this, the amount of cell-bound C4b was found to increase in parallel with C3b on the cell surface, and the degree of complement activation was directly proportional to the inoculating dose of CMV; minimal binding of C2 fragments was detected under all conditions (figure 4). Activation of complement in CMV-infected cells was very rapid: 150% of the total C3b present on the cell surface 30 min after incubation was deposited within the first 5 min ( figure 5) .
Reconstitution of complement-deficient and depleted serum. Both C1q and MBL initiated activation of complement and are sensitive to Ca 2ϩ ion depletion by EGTA-Mg 2ϩ treatment. To elucidate the role of these initiators, we used serum genetically deficient in C1q or MBL. Purified C1q and MBL were used to reconstitute the serum samples to rescue the complement activation by the respective pathways. Table 2 shows the C3b deposition on the surface of CMV-and mock-infected cells 4 days after infection. These were incubated with normal, deficient, and reconstituted serum. No difference in the increased C3b deposition on CMV-infected cells was observed when compared with normal, MBL-deficient, and MBL-reconstituted sera as a source of complement. In contrast, the C1q-deficient and C1q-depleted sera showed minimal C3b deposition on the surface of all cells. Partial restoration of C3b deposition on mock-infected and CMV-infected cells was accomplished by reconstitution of the sera with purified C1q. The binding of naturally occurring anti-CMV antibodies was also assessed. This confirmed that the serologic status of the serum used had no effect on C3b deposition on CMV-infected cells ( 
Discussion
In biologic fluids, C3 is continuously slowly hydrolyzed to form a metastable C3 (H 2 0) molecule which, in the presence of Mg 2ϩ ions, can bind factor B and form a fluid-phase C3 convertase. As a result of this "tickover" activation, C3b is continuously deposited in small amounts on all cells in the body [10, 11] . This activation is insensitive to chelation of Ca 2ϩ ions and is probably the major mechanism by which C3b was deposited on uninfected fibroblasts in the current study. Numerous other cell lines and primary cells can activate the alternative complement pathway to varying degrees: For example, B lymphocytes activate the alternative pathway in a CR2-dependent fashion [12] ; proximal tubular epithelial cells also activate the alternative pathway [13] . That the alternative pathway is the major route of activation of complement on primary fibroblasts is indicated by the continued complement activation in the absence of Ca 2ϩ (table 1, figure 3) . A contribution of the classical pathway is suggested by the finding that C1q-deficient or -depleted sera caused much less deposition of C3 fragments on these cells (table 2) .
Infection of fibroblasts with CMV resulted in a 3-to 4-fold increase in C3b deposition compared with mock-infected controls. This additional activation was Ca 2ϩ ion-dependent (table  1, figure 3) , which is strongly suggestive of classical pathway activation. Initially, we suspected that this increased complement activation was mediated by anti-CMV antibodies, as antibodies are the principal activator of the classical pathway. However, complement activation on CMV-infected cells was equivalent when incubated with serum samples containing IgG or IgM anti-CMV antibodies, which bound to the infected cells, or on samples devoid of such antibodies (figures 1, 2) . Involvement of the classical pathway was confirmed by demonstration of increased C4b-deposition on the surface of infected cells compared with mock-infected controls (figure 4). Negligible C2a binding was observed, and we surmise that this is because C2a is associated with C4b via a weak magnesium-dependent interaction that would not survive the processing for flow cytometry with EDTA-containing solutions. In contrast, both C4b and C3b are covalently attached to the surface following activation.
Calcium-dependent activation of complement can also be achieved by the lectin pathway utilizing MBL, independent of C1 [14, 15] . By using sera deficient in MBL or deficient in or depleted of C1q, we found that MBL deficiency did not influence complement activation by CMV-infected cells, whereas absence of C1q ablated CMV-induced complement activation (table 2) . This, together with the lack of effect of antibody binding, indicates a direct binding of C1q to CMV-infected cells. The data effectively eliminate a role for MBL, although MBL plays a role in the activation of complement by the purified virions of another herpesvirus, HSV, and by human immunodeficiency virus (HIV) [16, 17] .
Antibody-independent activation of the classical complement pathway has been reported for isolated Epstein-Barr virus (EBV) and HIV virions via direct interaction of gp41 and C1q [18] [19] [20] . We previously reported equal contributions of the classical and alternative complement pathways to activation on purified CMV virions incubated with nonimmune sera [21] . However, infection of cells with other herpesviruses, HSV and EBV, resulted in increased activation only of the alternative pathway [2, [22] [23] [24] [25] . This is in stark contrast to the increased classical pathway activation we found on CMV-infected cells. Cells infected with HIV or respiratory syncytial virus exhibit increased classical complement pathway activation, but always in association with increased alternative pathway activation [26] [27] [28] [29] [30] [31] . Furthermore, cells infected with viruses such as HIV and HSV show greatly increased complement activation in the presence of naturally occurring specific anti-viral antibodies in the serum [2, 23-5, 29, 30] . This contrasts with our findings in CMV-infected cells, where the presence of anti-CMV antibody, despite binding to the cell, had no effect on the degree of complement activation.
The finding that the presence of specific anti-CMV antibodies did not have a significant effect on complement activation by CMV-infected fibroblasts was unexpected. Anti-CMV IgG antibodies might fail to bind C1q because the viral epitopes on the cell surface are expressed at very low density, such that C1q binding sites are not formed. Such an explanation does not hold for IgM antibodies, because a single IgM antibody provides a C1q binding site. However, we found no increased binding of IgM from IgM-seropositive serum to infected cells compared with mock infection controls (data not shown). This finding indicates that the epitopes detected by the anti-CMV IgM antibody are expressed in negligible amounts on the surface of infected cells. The clinical tests for IgM antibody utilize whole virions (AXSYM) or recombinant CMV proteins (IMX); the panel of recombinant proteins used in the latter test includes none that are expressed on the viral envelope, and it is thus likely that none are expressed on the surface of infected cells [32] . The presence of a strong IgM reactivity in the clinical tests therefore does not necessarily equate with an IgM response to infected cells.
How then does CMV infection of cells increase classical complement activation independent of antibody? There could be a direct interaction of C1q with a cell-surface CMV-encoded protein, such as that identified for HIV envelope protein gp41 [33] , or CMV infection may up-regulate the expression of a hostencoded C1q-binding protein, such as the globular C1q receptor [34] . Alternatively, changes in the cell membrane may cause direct activation of C1q. Others have reported that an increase in positively charged lipids, phosphatidylserine (PS), or phosphatidylethanolamine in the outer leaflet of the membrane activates the alternative complement pathway [35, 36] , whereas increased classical pathway activation is associated with increased amounts of negatively charged lipids, such as cardiolipin, phosphatidylglycerol, and phosphatidylinositol [37] . While increased PS levels have been reported in the outer leaflet of CMV-infected cells, leading to increased procoagulant activity [38] , the status of negatively charged lipids in the outer leaflet of CMV-infected cells is unknown. Our future investigations will center around attempts to assess the alterations in these lipids and in cellular charge on CMV-infected cells. We will also attempt to isolate CMV or host-encoded proteins that bind directly to C1q in an attempt to explain the increased complement activation.
